Gilead Shares Slide After Light HIV Drug Sales Hit Q1 Earnings

Loading...
Loading...
  • Gilead Sciences Inc GILD reported lower than expected Q1 earnings with EPS of $2.08, slightly below the analyst consensus estimate of $2.09 but higher than $1.68 last year.
  • Sales of $6.42 billion missed the consensus of $6.74 billion but grew 16% Y/Y.
  • Revenue from COVID-19 treatment, Veklury, was $1.5 billion and excluding Veklury, total sales decreased 11% Y/Y to $4.9 billion.
  • Sales of HIV treatments declined 12% to $3.7 billion as Hepatitis C drug revenue fell 30% to $510 million.
  • Cancer drugs Yescarta and Tecartus generated higher sales of $160 million and $31 million, respectively. Trodelvy, which Gilead recently acquired, brought in $72 million.
  • Guidance: For FY20, the company expects adjusted income of $6.75-$7.45, in line with the analyst consensus of $7.17. It guided for revenue of $23.7 billion to $25.1 billion in full-year product sales, versus analyst consensus of $24.78 billion.
  • Price Action: GILD shares are down 2.3% at $62.37 in the premarket session on the last check Friday.
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...